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Abstract
Background: We have previously shown in pancreatic ductal adenocarcinoma (PDAC) cells that the SRC inhibitors
PP2 and PP1 effectively inhibited TGF-β1-mediated cellular responses by blocking the kinase function of the TGF-β
type I receptor ALK5 rather than SRC. Here, we investigated the ability of the clinically utilised SRC/ABL inhibitor
dasatinib to mimic the PP2/PP1 effect.
Methods: The effect of dasatinib on TGF-β1-dependent Smad2/3 phosphorylation, general transcriptional activity,
gene expression, cell motility, and the generation of tumour stem cells was measured in Panc-1 and Colo-357 cells
using immunoblotting, reporter gene assays, RT-PCR, impedance-based real-time measurement of cell migration,
and colony formation assays, respectively.
Results: In both PDAC cell lines, dasatinib effectively blocked TGF-β1-induced Smad phosphorylation, activity of 3TPlux
and pCAGA(12)-luc reporter genes, cell migration, and expression of individual TGF-β1 target genes associated with
epithelial-mesenchymal transition and invasion. Moreover, dasatinib strongly interfered with the TGF-β1-induced
generation of tumour stem cells as demonstrated by gene expression analysis and single cell colony formation.
Dasatinib also inhibited the high constitutive migratory activity conferred on Panc-1 cells by ectopic expression of
kinase-active ALK5.
Conclusions: Our data suggest that the clinical efficiency of dasatinib may in part be due to cross-inhibition of
tumour-promoting TGF-β signalling. Dasatinib may be useful as a dual TGF-β/SRC inhibitor in experimental and clinical
therapeutics to prevent metastatic spread in late-stage PDAC and other tumours.
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Background
Despite significant progress in the biology of pancreatic
ductal adenocarcinoma (PDAC), treatment options for
affected patients are still very limited and far from being
curative with the exception of surgery (R0 resection).
Chemotherapy is complicated by the desmoplastic na-
ture of the complex mircoenvironmental architecture of
the tumour tissue which is known to favour metastasis
and chemoresistance of tumour cells.
Due to its overexpression in PDAC and its various func-
tions in driving tumour suppression, the non-receptor
tyrosine kinase SRC represents a promising biological
target in experimental and clinical approaches to treat
PDAC [1–3]. Dasatinib (N-(2-chloro-6-methyl- phenyl)-
2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyri-
midin-4- ylamino)thiazole-5-carboxamide; BMS-354825,
Sprycel), a tyrosine kinase inhibitor originally developed
against BCR-ABL and SRC [4] and currently used in the
treatment of CML [5] and Philadelphia chromosome-
positive acute lymphoblastic leukemia (reviewed in [6]),
has also shown promise in the treatment of various epi-
thelial tumours [6] including pancreatic cancer. Dasatinib-
mediated inhibition of SRC slowed tumour progression
and metastasis of human PDAC cells in an orthotopic
mouse model [7], and stimulated migration, invasion, and
apoptosis in human [8] and murine [9] PDAC cells. More-
over, dasatinib inhibited metastasis in a mouse model of
PDAC but failed to suppress primary tumour growth and
prolong survival [7]. Along the same lines, a phase II study
found that dasatinib as a single-agent did not have clinical
activity as first-line therapy in patients with metastatic
PDAC [10].
Several preclinical studies have shown that dasatinib can
potentiate the antitumoural action of various other anti-
cancer drugs (reviewed in [11]. For instance, dasatinib
synergized with gemcitabine to induce anti-proliferation
and apoptosis in the pancreatic cancer cell line MIA
PaCa-2 by decreasing the levels of ALDH1A1, a marker
of tumour-initiating/cancer stem cells [12]. Interest-
ingly, 2/8 patients with pancreatic cancer (both
gemcitabine-refractory) who received both gemcita-
bine and dasatinib showed a partial response (stable
disease ≥6 months) [13]. When dasatinib was combined
with gemcitabine and erlotinib (an epidermal growth
factor-receptor (EGF-R) inhibitor), it inhibited the growth
of xenografts of both sensitive and resistant PDAC cells in
vivo without increasing toxicity [14]. More recently, con-
comitant targeting of SRC, EGF-R, and transforming
growth factor (TGF)-β has been suggested as a novel
therapeutic approach in pancreatic cancer [15].
Although originally developed as an inhibitor of
BCR-ABL and SRC [16], dasatinib, in drug affinity chro-
matography experiments was shown to interact with over
40 kinases, including SRC family kinases (SFKs), receptor
tyrosine kinases, serine/threonine kinases (STK), MAP
kinases, and EphA2 [17]. One of the STKs identified with
this approach was the type I receptor for TGF-β (TβRI,
also termed activin receptor-like kinase 5, ALK5) [18].
TGF-β1 is a pleiotropic growth factor that controls several
aspects of tumour cell behavior such as proliferation,
angiogenesis, desmoplasia, cell migration/invasion, and
metastasis. It has a central role in the initiation and pro-
gression of PDAC [19] which is evident from the observa-
tion that its aberrant expression in advanced tumour
stages is associated with decreased survival in PDAC
patients [20], and that the TGF-β1 signalling pathway is
among the 12 core pathways that are genetically altered in
100 % of PDAC tumours [21]. Besides ALK5, TGF-β1 re-
quires a second membrane-bound STK receptor, desig-
nated type II (TβRII), for signal transmission into cells.
Upon phosphorylation by TβRII, ALK5 initiates canonical
Smad as well as non-Smad signalling pathways [22] that
together mediate the promigratory and proinvasive effects
of TGF-β. For PDAC, this is evident from the Panc-1
orthotopic mouse model in which ectopic expression of
kinase-active ALK5 (ALK5T204D) strongly enhanced me-
tastasis [23] while pharmacologic inhibition of endo-
genous ALK5 suppressed it [24]. Targeting ALK5 in vivo
is therefore a feasible approach to the treatment of PDAC
and other carcinomas.
Like SRC, TGF-β/ALK5 signalling is currently targeted
in the experimental and clinical treatment of various
tumours. Given i) the interaction of dasatinib with ALK5
[18, 25], ii) the structural similarity of dasatinib with the
experimental SRC inhibitors PP2 and PP1, and iii) the
ability of PP2 and PP1 to effectively inhibit the ALK5
kinase activity as well as TGF-β1-induced prooncogenic
responses [26, 27], we hypothesized that dasatinib
should be able to block TGF-β1 signalling towards mi-
gratory, invasive and prometastatic outcomes. That dasa-
tinib may possess potential efficacy against profibrotic
TGF-β signalling in vivo was suggested by preclinical
studies, in which dasatinib treatment of scleroderma and
normal fibroblasts led to decreased production of extra-
cellular matrix proteins [28]. In light of the clinical use
and efficacy of dasatinib, it is mandatory to understand
its molecular mode of action in vivo including possible
side-effects, regardless of whether they are adverse or
beneficial for the patients.
To investigate the effect of dasatinib on TGF-β/ALK5
signalling in PDAC, we employed two TGF-β sensitive cell
lines (Panc-1, Colo-357) that have been used in orthotopic
mouse models of PDAC for evaluation of TGF-β antitu-
mour activity in vivo [23, 29]. Using impedance-based
real-time measurement of cell migration, we show here
that dasatinib strongly and dose-dependently inhibited
TGF-β1-induced migratory responses in vitro. As a result
of dasatinib inhibition, activation of Smad2/3, upregulation
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of TGF-β transcriptional reporter genes as well as EMT/
migration/invasion-associated gene expression in PDAC-
derived cell lines was compromised. These results have
implications for the use of dasatinib in experimental
therapeutics, providing a molecular explanation for the
reduction in the cells’ migratory response and an in vivo
correlate for its anti-metastatic action. Furthermore, our
data suggest that this agent based on its dual effect on
protumourigenic TGF-β and SRC signalling pathways may
be useful in the treatment of late stage metastatic disease
in PDAC.
Results
Dasatinib blocks TGF-β1-induced Smad2/3 activation in
PDAC cells
In order to test whether dasatinib can inhibit ALK5
function, we measured its effect on TGF-β1-induced
C-terminal phosphorylation of Smad2 and Smad3
(p-Smad2C/3C), reflecting their state of activation. To
this end, dasatinib dose-dependently inhibited TGF-β1-
induced p-Smad2C and p-Smad3C in both Panc-1 and
Colo-357 cells with the greatest effects seen at concentra-
tions >0.1 μM (Fig. 1). A comparison of signal strengths
between Panc-1 and Colo-357 cells after quantification by
densitometry revealed that the dasatinib effect on
both p-Smads was more pronounced in Panc-1 cells
(Fig. 1).
Dasatinib blocks TGF-β1-induced reporter gene activity
The above data showed that TGF-β1-induced Smad2
and Smad3 activation was sensitive to dasatinib inhib-
ition. Hence, we wondered whether this effect of dasati-
nib on the central mediators of TGF-β signalling would
have consequences for Smad-mediated transcriptional
activation of TGF-β1 target genes. To this end, cells
were transiently transfected with the TGF-β reporter
genes pCAGA(12)-luc or 3TPlux. While pCAGA(12)-luc
is Smad-specific and responds to binding of Smad3/4 ra-
ther than Smad2/4 to the Smad binding elements (SBEs)
in this plasmid [30], the 3TPlux plasmid contains
promoter sequences from the plasminogen activator-
inhibitor-1 gene and is responsive to both Smad and
non-Smad pathways [31]. Treatment of Panc-1 cells with
a combination of TGF-β1 and dasatinib strongly sup-
pressed the response of both pCAGA(12)-luc and 3TPlux
to TGF-β1 induction in a dose-dependent manner (Fig. 2),
and at a concentration of 10 μM was equally effective in
suppressing reporter gene activity as the established ALK5
inhibitor SB431542 at 5 μM (Fig. 2). In contrast, the SRC
inhibitor bosutinib (SKI-606, IC50 = 1.2 nM) was unable to
interfere with TGF-β transcriptional activity. Thus, dasati-
nib appears to be a powerful inhibitor of transcriptional
responses to TGF-β in PDAC-derived cell lines.
Dasatinib blocks TGF-β1-induced expression of genes
associated with EMT, migration/invasion and stemness
Next, we asked whether dasatinib would also affect
TGF-β1-induced upregulation of genes involved in EMT,
cell migration, and invasion. Dasatinib at 10 μM effect-
ively prevented the TGF-β1-induced downregulation of
E-cadherin in Panc-1 cells and dramatically inhibited
TGF-β1 induction of N-cadherin, vimentin, MMP2,
MMP9, Slug and Snail in Colo-357 and Panc-1 cells as
demonstrated by quantitative RT-PCR (qPCR, Fig. 3a)
and immunoblotting (Fig. 3b). Although TGF-β induc-
tion of Snail protein in Colo-357 cells and N-cadherin
protein in Panc-1 cells was only moderate, levels were
clearly reduced upon dasatinib treatment (Fig. 3b). To
show that the dasatinib-induced changes were caused by
inhibition of ALK5 rather than SRC, we treated Colo-
357 and Panc-1 cells, as above in the reporter gene
assays (Fig. 2), with either SB431542 or bosutinib and
repeated the qPCR analysis for two central regulators of
TGF-β-induced EMT, Slug and vimentin (Fig. 3c). While
SB431542 effectively abolished the TGF-β effect on Slug
and vimentin mRNA levels in both cell lines, bosutinib
lacked statistically significant effects (Fig. 3c).
Since this gene expression profile suggested that dasa-
tinib might be able to interfere with TGF-β1-induced
EMT and partial EMT has been shown to be associated
with the aquisition of stem cell traits [32], we subjected
Panc-1 cells to a long-term treatment with TGF-β1 ac-
cording to a previously published protocol [32] to study
the effect of dasatinib on the induction of stem cell gene
expression. To this end, a 14-day exposure to TGF-β1
resulted in the upregulation of several pluripotency-
associated genes: The TGF-β ligand superfamily mem-
bers βA activin and BMP2, the membrane-associated
markers CD90, CD105 (also termed endoglin, a TGF-β
coreceptor), and the transcriptional regulators OCT4
(the stem cell associated OCT4A isoform) and UTF1
(Fig. 4). Moreover, we observed downregulation of the
adhesion molecule NCAM1 (Fig. 4a) and, surprisingly,
of the xenobiotic transporter ATP-binding cassette sub-
family G member 2 (ABCG2) (Fig. 4). Intriguingly, the
TGF-β1 effect on all genes tested was effectively inhib-
ited by concomitant treatment with dasatinib (Fig. 4a).
To verify the possibility that dasatinib is able to block
the TGF-β/EMT-induced generation of cells with stem
cell character, we repeated the 14-day treatment of
Panc-1 cells with TGF-β1 in the absence or presence of
dasatinib, or SB431542 as control (long-term treatment of
these cells with bosutinib was not possible due to its
toxicity). Subsequently, we employed the colony formation
assay (CFA) to assess the number of cells with stem cell
features by virtue of their ability to generate from a single
cell a microscopically discernible clone or colony [33, 34].
A quantitative analysis by counting revealed that both
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dasatinib, and SB431542 as control, strongly decreased
the number of colonies/clones that arose from TGF-β1-
treated cultures relative to untreated controls (Fig. 4b).
Together, our data suggest that dasatinib interferes with
TGF-β-induced EMT and stem cell generation and raise
the possibility that it can block the generation of tumour-
initiating cells in vivo.
Dasatinib blocks TGF-β1-induced cell migration
Given the ability of dasatinib to block TGF-β1-induced
EMT and cell motility-associated gene expression as well
as Smad activation and transcriptional activity in
conjunction with the requirement for Smad3 for TGF-β1-
dependent migration of PDAC cells [35], we hypothesized
that dasatinib also interferes with TGF-β1-induced cell
motility in PDAC cells. To this end, dasatinib at the
10 μM concentration abolished both basal and TGF-β1-
stimulated cell migration in both Panc-1 and Colo-357
cells (Fig. 5a). To determine whether this antimigratory
effect of dasatinib was dose-dependent and to be able to
calculate the concentration of half-maximal inhibition, we
serially diluted the dasatinib and repeated the migration
assays with lower concentrations. Interestingly, a concen-
tration as low as 0.01 μM afforded an approximately 50 %
reduction in migration activity in both cell types (Fig. 5b,
magenta curves). With respect to inhibition of TGF-β1-
stimulated migration, the dasatinib effect was comparable
to that of SB431542 affording complete inhibition (Fig. 5c),
however, dasatinib unlike SB431542 also suppressed the
increase in basal migratory activity which in contrast to
Colo-357 cells was quite high in Panc-1 cells (Fig. 5c).
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Fig. 1 Immunoblot analysis of TGF-β1-induced R-Smad activation in Panc-1 and Colo-357 cells treated with dasatinib. Panc-1 and Colo-357 cells were
stimulated with 5 ng/ml TGF-β1 for 1 h in the presence of vehicle (DMSO, 0.1 % v/v) or the indicated concentrations of dasatinib, and subsequently
evaluated by immunoblotting for C-terminal phosphorylation of Smad2 (p-Smad2C, upper two panels) and Smad3 (p-Smad3C, lower two panels).
Equal loading of total protein was verified with antibodies to Smad2 and Smad3, respectively. Below the immunoblots is a graphic representation of
the results from densitometric analysis of p-Smad band intensities after normalization with those for the respective total Smad proteins
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migration (which precedes TGF-β1-stimulated migration)
was SRC-dependent [36], suggesting that in Panc-1 cells
dasatinib acts as a dual inhibitor of ALK5 and SRC-
mediated migration. Together, these results clearly show
that dasatinib, in a very sensitive and effective fashion,
blocked TGF-β1-induced migration/invasion in PDAC
cells in vitro. This data together with those presented in
Figs. 1, 2, and 3 strongly support our contention that dasa-
tinib represents a powerful inhibitor of TGF-β1-induced
cell motility by inhibiting ALK5 rather than SRC or other
SFKs.
Dasatinib inhibits the high constitutive migratory activity
of Panc-1 Cells expressing kinase-active ALK5
As shown previously, the experimental SRC inhibitors
PP2 and PP1 strongly interfered with the high constitu-
tive migratory activity conferred on these cells by ectopic
expression of ALK5T204D, a kinase-active version of
ALK5 that harbors an activating point mutation in its
glycine- and serine-rich (GS) domain [37] and does not
rely on ligand binding, complex formation and phos-
phorylation by the TβRII kinase in order to signal. To
test whether dasatinib was capable of mimicking the
PP1/PP2 effect, we subjected Panc-1-ALK5T204D cells
(one of several individual and previously characterised
clones [23]) to the RTCA migration assay. Notably, both
dasatinib (Fig. 6a) and SB431542 (Fig. 6b) strongly
reduced both migration directed by the exogenously
expressed ALK5T204D receptors and the extra portion
induced by stimulation of endogenous (non-mutant)
receptors in response to their activation by recombinant
TGF-β1 ligand. These data are consistent with the
results from dasatinib inhibition of ligand-induced cell
migration in wild-type cells (see Fig. 5) and confirm that
dasatinib targets the ALK5 kinase function or events
downstream thereof for inhibition.
Discussion
The tyrosine kinase inhibitor dasatinib at low concentra-
tions (IC <1.0 nM) potently inhibits ABL and SFKs. At
higher concentrations it also inhibits other TKs and
STKs such as ALK5, p38 MAPK, AKT, and FAK, all of
which have been implicated in TGF-β signalling either
in the canonical branch (ALK5), as downstream media-
tors of Smads (AKT, FAK, p38 MAPK) or in the non-
canonical branch (p38 MAPK, FAK) [22]. ALK5 was
originally identified by drug affinity chromatography to
interact directly with dasatinib [18]. Later, this observa-
tion was confirmed in docking studies using the previ-
ously reported crystal structure of the ALK5 cytoplasmic
domain. Here, the binding of dasatinib to ALK5 pre-
sented with the highest score when compared to the
structurally related bosutinib, the commercially available
ALK5 inhibitor LY-364947, and dorsomorphin [25].
Likewise, we have shown previously that PP2 and PP1,









































Fig. 2 Treatment of Panc-1 cells with dasatinib decreases the sensitivity of TGF-β/Smad-responsive reporters to TGF-β1 stimulation. Panc-1 cells
were transfected on day 1 with either pCAGA(12)-luc (upper graph) or 3TPlux (lower graph), and the Renilla luciferase-encoding vector pRL-TK-luc
using LipofectAmine 2000. Twenty-four h after the start of transfection, cells were stimulated with TGF-β1 for another 24-h period in the presence
of 0.1 % DMSO or the indicated concentrations of dasatinib, SB431542, or bosutinib, followed by dual luciferase measurements. Data represent
firefly luciferase values normalised with those for Renilla luciferase (displayed as relative (rel.) luciferase activities with those for DMSO/non-TGF-β1-
treated cells set arbitrarily at 1) and are the mean ± SD from three independent assays. Asterisks indicate significance of TGF-β1-treated cells vs.
the respective untreated control (n = 3)
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attenuated various oncogenic responses to TGF-β1 in ma-
lignant PDAC cell lines and strongly inhibited ALK5 kin-
ase activity in in vitro kinase assays [26]. In the present
study, we have tested in the Panc-1 and Colo-357 cell lines
the prediction that dasatinib can mimic the action of PP2
and PP1 on TGF-β signalling. We found that dasatinib
effectively blocked TGF-β1-dependent reporter gene
activity, Smad2/3 activation and cell migration. The
inhibitory effect of dasatinib (IC50 = 0.8 nM for SRC in
cell-free assays) on ligand-induced reporter gene activity
was not dependent on SRC since it was not mimicked by
another SRC inhibitor, bosutinib (IC50 = 1.2 nM, [38]).
Moreover, dasatinib strongly inhibited migration driven by
the ALK5T204D mutant (Fig. 6). The inhibitory effect of
dasatinib on TGF-β1/ALK5-mediated cell motility corre-
sponded well with the potency of this agent to inhibit
various TGF-β1-regulated marker genes involved in EMT,
migration/invasion, and a cancer stem cell phenotype.
Consistent with this, qPCR assays revealed that dasatinib
suppressed TGF-β1 induction of MMP2, MMP9, N-
cadherin, vimentin, Snail and Slug in Panc-1 and Colo-357
cells. In Panc-1 cells, dasatinib also attenuated downregu-
lation of the adhesion molecules E-cadherin and
NCAM1, together providing a molecular explanation
for the anti-migratory/anti-invasive effect of dasatinib.
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Fig. 3 Dasatinib blocks TGF-β1-induced expression of genes involved in EMT and cell migration/invasion. a Colo-357 (upper graph) and Panc-1
cells (lower graph) cultured for 24 h in the absence or presence of TGF-β1 (5 ng/ml) and either DMSO or dasatinib (10 μM) were subjected to RNA
isolation and qPCR-based determination of the indicated genes. Data are plotted relative to untreated DMSO-treated control cells (set arbitrarily at 1)
and represent the mean ± SD from three independent experiments after normalisation to β-actin and TBP. Asterisks indicate a significant difference
between dasatinib + TGF-β1-treated cells and DMSO + TGF-β1-treated cells (n = 3). b Colo-357 and Panc-1 cells cultured for 48 h in the absence or
presence of TGF-β1 (5 ng/ml) and either DMSO or dasatinib (10 μM) were subjected to immunoblot analyses of the indicated proteins and β-actin as a
loading control. One representative blot is shown for each cell line. c Colo-357 and Panc-1 cells cultured for 24 h in the absence or presence of TGF-β1
(5 ng/ml) and either DMSO, SB431542 (SB, 5 μM) bosutinib (Bosu, 10 μM) were subjected to qPCR-based determination of Slug and vimentin. Data
represent the mean ± SD from three independent experiments. Asterisks indicate a significant difference between SB + TGF-β1-treated cells
and DMSO + TGF-β1-treated control cells (n = 3)
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induced upregulation of several stem cell-associated
genes, some of which are either members of the
TGF-β superfamily of ligands (βA activin, BMP2) or
function as a co-receptor for TGF-β (CD105/endo-
glin) and strongly decreased the number of colony-
forming units derived from long-term TGF-β1-treated
cells assumed to derive from cancer stem cells. From
these data, we conclude that dasatinib targets ALK5
for inhibition of TGF-β-induced cell motility in vitro
and likely also other EMT-associated changes such as
cancer stem cell differentiation.
Gordian and colleagues [25] studied the combined ef-
fects of dasatinib and TGF-β on A549 NSCLC cells.
When combined with TGF-β1 stimulation, dasatinib
induced apoptosis in EGF-R mutant cells along with
upregulation of pro-apoptotic BIM protein. Unfortu-
nately, cell motility responses were not analysed in this
study. For analysis of Smad2 and Smad3 activation by
TGF-β1, these authors used a single concentration of
100 nM dasatinib rather than providing a dose–response
curve with higher concentrations. With this dose they
observed an increase in the levels of p-Smad3C com-
pared to levels seen with TGF-β1 alone. Interestingly, we
also observed in PDAC cells a tendency for an increase
or at least a lack of effect in the concentration range
of 10–100 nM, which was particularly evident in the
Colo-357 cell line (see Fig. 1).
Several drugs have been developed for blocking TGF-β
signalling that are in various stages of experimental and
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Fig. 4 Dasatinib blocks the TGF-β1-induced generation of cells with stem cell character. a Panc-1 cells were treated or not for 14 d with TGF-β1
(5 ng/ml) and either DMSO or dasatinib (10 μM) followed by qPCR-based determination of the indicated stem cell-associated genes. Data are
plotted relative to untreated DMSO-treated control cells and represent the mean ± SD from three independent experiments. Asterisks indicate a
significant difference between the DMSO + TGF-β1 and the dasatinib + TGF-β1 treated cells (n = 3). b Panc-1 cells were treated or not for 14 d with
TGF-β1 (5 ng/ml) and either DMSO, dasatinib (10 μM), or SB431542 (5 μM) followed by colony formation assay. Data represent the mean ± SD from
three independent assays. Asterisks indicate a significant difference relative to the non-TGF-β1-treated control cells (n = 3)
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signalling include blocking i) the binding of TGF-β to its
receptors, ii) the ALK5 kinase using small molecules that
act as competitive inhibitors for its ATP-binding site
(SB431542, SB505124, SD-093, SD-208, LY580276, and
Y2109761, a novel TβRI and TβRII dual inhibitor), and
iii) Smad intracellular signal transduction via the Smad3
inhibitor SIS3 [39]. However, although many of these
drugs show promise in pre-clinical studies, the dual role
of TGF-β in tumour progression requires a deeper
understanding of the TGF-β signalling crosstalk with
other pathways in order to design successful therapeutic
approaches and protect the patients from undesired side
effects.
Taken together, our results clearly show that dasatinib
can block the TGF-β1-dependent cell motility at concen-
trations as low as 0.01 μM. However, this extremely
sensitive and potent effect of dasatinib, particularly in
Panc-1 cells (see Fig. 5), may have resulted from
combined inhibition of ALK5 and SRC since we have
previously shown that SRC contributed to TGF-β1-
mediated cell migration without affecting TGF-β1/
ALK5-induced activation of Smad2 and Smad3. This dif-
ferential contribution of SRC may explain why dasatinib
was able to block cell migration at much lower concen-
trations than phosphorylation of Smad2C/3C (compare
Figs. 1 and 5). The higher efficacy of dasatinib in block-
ing TGF-β1-induced cell motility may be due to co-
inhibition of p38 MAPK, the activation by TGF-β1 of
which is SRC-dependent [40] and required for cell mi-
gration in Panc-1 cells (H.U., unpublished observation).
Experiments are currently underway to solve this issue.
That dasatinib likely acted on SRC in the migration as-
says was evident from its suppressing effect on basal mi-
gration activity in Panc-1 cells which was previously
shown to be SRC-dependent [36]. Notably, TGF-β stimula-
tion of p38 MAPK activation and cell invasion requires
Time [h] 
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Fig. 5 Effect of dasatinib on TGF-β1-induced cell migration in PDAC cell lines. Overnight starved Panc-1 or Colo-357 cells were resuspended in
growth medium with 1 % FCS and seeded into the wells of a CIM-Plate 16 (60,000/well) of the RTCA DP instrument. Cells were allowed to
migrate in the presence of TGF-β1 (5 ng/ml, added to both the lower and upper compartment of each well) and either vehicle or dasatinib
at the indicated concentrations (a & b) or SB431542 (c) as indicated by the colour code. Changes in impedance resulting from cells that have
migrated to the bottom side of the membranes were recorded every 15 min and monitored for a total of 12 h (Panc-1) and 24 h (Colo-357). Data
are from one representative experiment out of three experiments performed in total and are presented as means ± SD of quadruplicate wells. In
each graph, significance was calculated for vehicle + TGF-β1 vs. dasatinib + TGF-β1 (a & b) or vs. SB431542 + TGF-β1 (c). The first time point at
which differences become significant are for Panc-1 cells: 10 μM: 0:30 (a, left-hand graph); 1 μM: 0:15; 0.1 μM: 0:15; 0.01 μM: 0:30 (b, left-hand
graph); 5 μM: 0:30 (c, left-hand graph); and for Colo-357 cells: 10 μM: 0:47 (a, right-hand graph); 1 μM: 1:04; 0.1 μM: 3:50; 0.01 μM: 4:35 (b, right-hand
graph); 5 μM: 0:30 (c, right-hand graph)
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SRC to phosphorylate TβRII [40]. Because this event is up-
stream of ALK5 activation, SRC is unlikely to be involved
in ALK5T204D-mediated cell migration consistent with the
very similar migration curves of dasatinib and SB431542-
treated cells.
In the light of our results, the possibility remains that
dasatinib’s therapeutic effects result to a large extent
from inhibition of TGF-β signalling rather than signal-
ling by its bona fide target SRC. That dasatinib can in-
deed compromise undesired effects of TGF-β in vivo
was suggested by preclinical studies in an in vitro model
of a fibrosing disorder in which dasatinib treatment of
scleroderma and normal fibroblasts led to decreased
production of extracellular matrix proteins [28]. The
suppressive effect of dasatinib on TGF-β signalling is
likely mediated by inhibition of the ALK5 kinase activity
and may be exploited therapeutically in more advanced
PDAC (when TGF-β1 expression and SRC activity are
high) to synergistically reduce invasion, metastasis and
eventually cancer stem cell formation. Consistent with
this, concomitant targeting of EGF-R, TGF-β and SRC
has been suggested as a novel therapeutic approach in
pancreatic cancer [15].
Conclusions
Understanding how anti-cancer drugs act in vivo is of
utmost importance for risk and treatment stratification
and for developing targeted combination therapies in ad-
vanced PDAC. TGF-β1 is a prometastatic ligand in pan-
creatic cancer which regulates EMT, cell migration/
invasion and cancer stem cell formation. Here, we show
that the BCR-ABL/SRC inhibitor dasatinib strongly
DMSO
DMSO + TGF 1
Dasatinib
Dasatinib + TGF 1




















DMSO + TGF 1
SB431542




















Fig. 6 Dasatinib inhibits cell migration induced by kinase-active ALK5. Cells (60,000/well) from a previously characterised clone of Panc-1-ALK5T204D
cells were seeded into a CIM-Plate 16 for measurement of cell migration. Cells were allowed to migrate in the absence or presence of exogenous
TGF-β1 (5 ng/ml) and either DMSO (0.1 %) or dasatinib (10 μM) (a) or SB431542 (5 μM) (b). Data shown are given as mean ± SD of quadruplicate wells
and were derived from one representative experiment out of three experiments performed in total. Significant differences in the cell index values
between vehicle treated (red curve) and dasatinib-treated (green curve) Panc-1-ALK5TD cells, and between vehicle + TGF-β1 treated (blue curve)
dasatinib + TGF-β1-treated (ochre curve) were first observed at the 1:00 h and all later time points
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interfered with these tumour-promoting responses, sug-
gesting that the clinical efficiency of dasatinib may be
due in part to cross-inhibition of TGF-β/ALK5 signal-
ling. Hence, dasatinib may be useful as a dual TGF-β/
SRC inhibitor in experimental and clinical therapeutics




TGF-β1 was obtained from ReliaTech (Wolfenbüttel,
Germany). Dasatinib was provided by Bristol-Myers
Squibb (UK) and bosutinib (SKI-606) was kindly do-
nated by Pfizer (USA). Stocks of these compounds were
prepared in dimethyl sulfoxide (DMSO) which at the
concentration used (0.1 %) had no measurable effect on
cellular activities (data not shown).
Cell lines, cell culture and treatment with TGF-β1 and
inhibitors
The PDAC cell lines Panc-1 and Colo-357 were main-
tained in standard culture medium consisting of RPMI
1640 supplemented with 10 % fetal calf serum (FCS), L-
glutamine, sodium pyruvate and 50 units/ml penicillin
and streptomycin. The generation and characterization
of individual cell clones from stable retroviral transduc-
tion of Panc-1 cells with a kinase-active mutant of ALK5
(T204D mutation) was described in detail in a previous
publication [23]. These cells were cultured in the
presence of 700 μg/ml geneticin (Life Technologies,
Darmstadt, Germany). For stimulation experiments, cells
were pretreated with DMSO or inhibitors (Dasatinib,
SB431542) for 30–60 min before the addition of TGF-β1.
The long-term treatment of Panc-1 cells with TGF-β1 was
performed in standard culture medium with 2 % FCS
according to a previously published protocol [32].
Immunoblot analysis
Inhibitor-treated cells were lysed in PhosphoSafe buffer
(Merck) and the protein concentrations determined with
the DC protein assay (Bio-Rad, München, Germany). Equal
amounts of cellular proteins were fractionated by SDS-
PAGE, transferred to PVDF membrane and immunoblotted
as described in detail earlier [26]. The antibodies used were:
β-actin (Sigma-Aldrich, #A1978), N-cadherin (BD Trans-
duction Lab. #610920), anti-phospho-Smad2(Ser465/467)
and anti-phospho-Smad3(Ser423/425), both from Cell
Signalling Technology (Frankfurt/Main, Germany),
Smad2 (Epitomics, Burlingame, CA, #1736-1), Smad3
(Abcam, Cambridge, UK, #ab40854), Snail (Cell
Signalling Technology, #4719), and vimentin (Sigma-
Aldrich, #V6630). In some experiments, the intensities
of bands were quantified by densitometry using NIH
image J.
Quantitative RT-PCR analysis
The procedure and the conditions for real-time quanti-
tative RT-PCR (qPCR) which was performed on an I-
cycler with IQ software (Bio-Rad) were published earlier
[23]. Primers were generally chosen to span exon-intron
boundaries. However because OCT4 is devoid of introns,
amplification of its mRNA required the removal of residual
genomic DNA from the isolated RNA. Therefore, RNA
was prepared with the NucleoSpin® RNA isolation kit
involving digestion with RNase-free DNase I (Macherey-
Nagel, Düren, Germany). Sequence information for ampli-
fication primers is provided in Additional file 1 Table S1
and in Ref. [41]. All values for the genes of interest were
normalised to those for β-actin and TBP, and relative gene
expression was calculated by the 2-ΔΔCt method.
Transient transfection and reporter gene assays
For reporter gene assays, Panc-1 cells were seeded in 96-
well plates and cotransfected on the next day (4 h, serum-
free) with LipofectAmine 2000 (Life Technologies), either
one of the two TGF-β-responsive promoter-firefly luci-
ferase reporter plasmids 3TPlux and pCAGA(12)-luc
(kindly provided by Drs. J. Massagué and S. Dooley, re-
spectively), and the Renilla luciferase encoding vector
pRL-TK-luc (Promega, Heidelberg, Germany). Each well
received the same total amount of DNA. Following re-
moval of the transfection mixture, cells were allowed to
recover overnight in standard growth medium and on the
following day were treated with TGF-β1 [5 ng/ml] and in-
hibitors or vehicle (added 1 h prior to the addition of
TGF-β1) for a total of 24 h. Cells were then lysed in Glo
lysis buffer (Promega) and luciferase activities determined
with the Dual Luciferase Assay System (Promega). In all
reporter gene assays, the data for each condition were
derived from six parallel wells and were corrected for
transfection efficiency with Renilla luciferase activity.
Real-time impedance-based measurement of cell
migration
We applied the xCELLigence RTCA technology (OLS,
Bremen, Germany) which represents a non-invasive and
label-free approach for continuous (real-time) monitor-
ing of cell migration and invasion on a cell culture level
(for review see [42]. Considering that growth factors or
their inhibitors may exert maximal effects at different
time points after treatment, it is useful to monitor cell
behaviour continuously and over a prolonged period of
time. The precise determination of peak migratory/inva-
sive activity of a given cell population may aid in deci-
phering the underlying mechanism of action of receptor
kinases and their inhibitors.
Migration experiments were performed using modified
16-well plates (CIM-Plates 16, OLS ). The setup of the
experimental device was described in detail earlier [27].
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To begin an experiment, overnight serum-starved cells
(30,000–60,000 per well) were mixed and preincubated
with vehicle or dasatinib in 100 μl of culture medium
containing 1 % FCS. After 30 min, TGF–β1 was added
to a final concentration of 5 ng/ml and cells were seeded
in the upper chambers. FCS, TGF-β1 and inhibitors had
been added before to the lower chambers at the same
concentrations (chemokinesis). After cell addition, CIM-
Plates 16 remained at room temperature in the laminar
flow hood for 30 min to allow cells to settle onto the
membrane. PBS was added to the empty space sur-
rounding the wells in order to prevent interference from
evaporation. Each condition was performed in quadru-
plicate with a programmed signal detection every
15 min for a total of 8–24 h depending on the cell type.
Data acquisition and analysis was performed with the
RTCA software (version 1.2, OLS).
Colony formation assay (CFA)
The CFAs are commonly used as survival assays to assess
the cytotoxic effects of a compound on cell lines and to
evaluate the efficacy of anticancer therapeutics. More re-
cently, CFAs became an interesting method in cancer
stem cell biology due to their potential to assess the cap-
acity of cells to produce progeny. The assay relies on the
assumption that only a cell which is largely undifferen-
tiated can give rise to a countable colony. Consequently,
the cell of origin must have features of a stem cell or pro-
genitor cell. The CFA assay was carried out according to
published protocols [33, 34]. Briefly, after treatment of
Panc-1 cells with TGF-β ± dasatinib, cells were detached
with Accutase, resuspended in culture medium and cen-
trifuged for 5 min at 400 g. Subsequently, supernatants
were discarded and cell pellets were resuspended in 1 ml
of culture medium. Fourhundred cells each were seeded
in three wells of a 6-well culture plate for each condition
and incubated for14 days. After incubation, medium was
aspirated, colonies were washed once in PBS, and fixed
with 1 ml 4.5 % (w/v) paraformaldehyde for 15 min.
Colonies were then stained with 0.1 % crystal violet for 1 h
and finally washed twice in ddH2O and air-dried overnight.
Colonies consisting of at least 50 cells were counted.
Statistical analysis
Statistical significance was calculated from at least
three independent experiments using the unpaired
Student’s t-test. Data were considered significant at p < 0.05.
The levels of significance are as follows: *, p < 0.05; **,
p ≤ 0.01; ***, p ≤ 0.001.
Additional file
Additional file 1: Primers used for qRT-PCR. (DOC 51 kb)
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